Increasing awareness, participation, funding and streamlining communication for MS trials.
4th December, 2014
Pharmaceutical company, Novartis, has released disappointing news that Gilenya does not slow disability in a clinical trial for primary progressive MS
26th November, 2014
The aim of this study is to investigate how personality and beliefs about MS affect adjustment to MS